Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
- 15 February 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (4) , 1654
- https://doi.org/10.1182/blood-2002-09-2923
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- The effect of treatment with Campath‐1H in patients with autoimmune cytopeniasBritish Journal of Haematology, 2001
- Pure red cell aplasiaBritish Journal of Haematology, 2000
- Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximabBlood, 2000
- CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.Journal of Clinical Oncology, 1998